Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT01614821Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Response Rate at 4 years. Started May 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01614821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614821.